Last reviewed · How we verify
XNW3009
At a glance
| Generic name | XNW3009 |
|---|---|
| Sponsor | Evopoint Biosciences Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XNW3009 in Health Subject (PHASE1)
- To Evaluate Drug Interactions Between XNW3009, Febuxostat, and Colchicine in Patients With Gout (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XNW3009 CI brief — competitive landscape report
- XNW3009 updates RSS · CI watch RSS
- Evopoint Biosciences Inc. portfolio CI